Medical imaging artificial intelligence company AIDOT (CEO Jeong Jae-hoon) announced on the 12th that it will unveil its strategy to enter the Chinese market with its AI cervical cancer diagnostic solution, 'Cerviray AI.'

AIDOT has been officially invited to the '2nd Boao Lecheng International Innovative Pharmaceuticals and Medical Devices Expo,' which will be held on November 20 in the Boao Lecheng International Medical Tourism Pilot Zone in Hainan Province, China.

Hosted by the Boao Lecheng Administration and organized by Guorun International Medical (国润国际医疗), the expo consists of a main forum and 11 breakout sessions, with approximately 1,500 on-site participants expected, including scholars from China and abroad, executives from global pharmaceutical and medical device companies, clinicians, and investment institutions.

At this event, AIDOT will introduce the Chinese launch and medium-to-long-term business strategy of Cerviray AI during the breakout session 'Asia-Pacific International Medical Innovation Summit.'

Prior to this, AIDOT signed an exclusive supply agreement for Hainan Province with Guorun.

To select a cervical cancer diagnostic solution to introduce to the Chinese market, Guorun compared and verified the technical performance of multiple products, ultimately selecting Cerviray AI as its partner product.

Unlike simple discrimination tools that merely distinguish between normal and abnormal conditions, Cerviray AI is known to have received high scores in the foreign partner's comparative evaluation because it provides clinical information that medical staff can actually utilize for diagnosis and follow-up monitoring.

Boao Lecheng is 'China's pilot clinical special zone' where unapproved overseas innovative medical products can be used first under special authorization; to date, over 600 overseas innovative pharmaceuticals and medical devices have initiated their first clinical uses in China here.

AIDOT plans to build clinical track records in Boao Lecheng before expanding across mainland China and subsequently extending into the Southeast Asian market.

Jeong Jae-hoon, CEO of AIDOT, stated, "The fact that our Chinese partner selected Cerviray AI after directly comparing and verifying multiple products signifies that our technological capabilities have been objectively recognized by global standards."

Korea Economic TV / 2026-10-12 / Deputy Managing Editor Jae-jun Yang